Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

39
Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002
  • date post

    22-Dec-2015
  • Category

    Documents

  • view

    223
  • download

    5

Transcript of Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Page 1: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Lectures 12 - 13

Genetics of Human Disease: Hemoglobinopathies

November 7 - 8, 2002

Page 2: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Learning Objectives

• Understand how the basic anatomy of a gene has a direct bearing on the occurrence of genetic disease.

• Know the normal and abnormal expression patterns of the hemoglobin genes.

• Understand the mutations that cause quantitative abnormalities in globin.– Unequal crossing over, and every other possible type

of mutation• Recognize mutations that cause qualitative

abnormalities in globin.– Missense mutations primarily

Page 3: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.
Page 4: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.
Page 5: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.
Page 6: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 5.2

Page 7: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.3

Page 8: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.2

Page 9: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.4

Page 10: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.5

Page 11: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.
Page 12: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.14

Page 13: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.15

Page 14: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.16

Page 15: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.
Page 16: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

α-thal is almost always related to unequal crossing over or deletions.

Rarely, loss of function of an α-globin gene arises from point mutations, but in contrast to β-thal, these mutations are in the minority.

Page 17: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.
Page 18: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.15

Page 19: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.17

Page 20: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.12

Example of unequal crossing over as a mechanism of inactivating the β-globin gene.

Page 21: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.13

Unequal crossing over between δ and β genes…clinically leads to a combined quantitative and qualitative abnormality (Lepore).

Notice that individuals with an anti-Lepore chromosome make normal amounts of δ and β , but also make the novel anti-Lepore hemoglobin.

Page 22: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.11

Loss of the normal termination codon near the end of β-globin gene

Loss of the normal termination codon near the end of -globin gene

Page 23: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.
Page 24: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.19

Mutations in the β globin promoter can give rise to β + thalassemia

Page 25: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.20

Splicing abnormalities lead to predictable phenotypes

Page 26: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.21

Most common cause of β+ thalassemia in Mediterranean is related to an abmormal splice acceptor site.

Page 27: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.22

Hgb E – this mutation gives rise to a quantitative abnormality (activation of a cryptic splice donor site) and a qualitative abnormality (missense mutation at codon 26)

Page 28: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.18

Page 29: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Untreated β thalassemia

Page 30: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Treatment of thalassemia major

Page 31: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.24

Page 32: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.25

Page 33: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.
Page 34: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Textbook Figure 6.26

Page 35: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

NEJM 347: 1162-1168, 2002

10 large Pakistani families with hemoglobinopathies

5 large Pakistani families without hemoglobin disorders

All carriers & married couples with 2 carriers genetic counseling

Page 36: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

NEJM 347: 1162-1168, 2002

Half-solid symbols represent those who are heterozygous for β-thalassemia

Solid symbols represent those with β-thalassemia major

Page 37: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

• Average cost of Fe chelation therapy is $4,400, or 10 times the average annual income.

• Treatment costs for 1 year – currently 4% of government health-expenditures.

• 183 / 591 (31%) of persons in families with an index case tested were carriers

• All carriers reported using the information provided in counseling

• “Testing of extended families is a feasible way of deploying DNA-based genetic screening in communities in which consanguineous marriage is common.”

Page 38: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Cao & Galanello, NEJM 347: 1202, 2002

Screening for β-thalassemia in Sardinia

Page 39: Lectures 12 - 13 Genetics of Human Disease: Hemoglobinopathies November 7 - 8, 2002.

Summary

• Understand how the basic anatomy of a gene has a direct bearing on the occurrence of genetic disease.

• Know the normal and abnormal expression patterns of the hemoglobin genes.

• Understand the mutations that cause quantitative abnormalities in globin.– Unequal crossing over, and every other possible type

of mutation• Recognize mutations that cause qualitative

abnormalities in globin.– Missense mutations primarily